Patients with type 2 diabetes belong to a high-risk group for heart failure; therefore, proactive examination of the physical findings and noninvasive imaging evaluation is required, as well as consideration of the indications for GLP-1 analogs and SGLT2 inhibitors in light of the heart failure risk exacerbation in this particular subgroup of patients. This evidence concerns the gene GCG and heart failure.